{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:22:26Z","timestamp":1790320946113,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ejim.2017.08.019","type":"journal-article","created":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T05:00:11Z","timestamp":1503118811000},"page":"6-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach"],"prefix":"10.1016","volume":"47","author":[{"given":"Pedro","family":"Iglesias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2017.08.019_bb0005","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"Ott","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejim.2017.08.019_bb0010","article-title":"Clinical development of immune checkpoint inhibitors","volume":"605478","author":"Ito","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ejim.2017.08.019_bb0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.ejim.2017.08.019_bb0020","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.18632\/oncotarget.13315","article-title":"Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejim.2017.08.019_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2017.08.019_bb0030","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/CCO.0000000000000293","article-title":"Endocrinological side-effects of immune checkpoint inhibitors","volume":"4","author":"Torino","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"3","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0040","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.394","article-title":"Immune-related adverse events from immune checkpoint inhibitors","volume":"3","author":"Marrone","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2017.08.019_bb0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejim.2017.08.019_bb0050","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"1","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.ejim.2017.08.019_bb0055","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0060","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"3","author":"Abdel-Rahman","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0065","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1188\/16.CJON.405-410","article-title":"Update on new therapies with immune checkpoint inhibitors","volume":"4","author":"Peterson","year":"2016","journal-title":"Clin J Oncol Nurs"},{"issue":"9","key":"10.1016\/j.ejim.2017.08.019_bb0070","article-title":"Current status and perspectives in translational biomarker research for PD-1\/PD-L1 immune checkpoint blockade therapy","volume":"27","author":"Ma","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0075","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"8","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.08.019_bb0080","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"10","author":"Maio","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0085","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.08.019_bb0090","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx151","article-title":"Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions","author":"Atkins","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0095","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"5","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"4","author":"Calabro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ejim.2017.08.019_bb0105","first-page":"1767","article-title":"Tremelimumab: research and clinical development","author":"Comin-Anduix","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ejim.2017.08.019_bb0110","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"8","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0115","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"26","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.08.019_bb0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial","volume":"1","author":"Reck","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0125","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.08.019_bb0130","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"33","author":"Armand","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"1","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0140","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"11","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0145","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2016.07.003","article-title":"Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma","volume":"65","author":"Kirchberger","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejim.2017.08.019_bb0150","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"11","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2017.08.019_bb0155","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11102-016-0736-z","article-title":"Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects","volume":"6","author":"Bellastella","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.ejim.2017.08.019_bb0160","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"14","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejim.2017.08.019_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review","volume":"1","author":"Juszczak","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0170","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1634\/theoncologist.2012-0464","article-title":"Ipilimumab for patients with advanced mucosal melanoma","volume":"6","author":"Postow","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ejim.2017.08.019_bb0175","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","article-title":"Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer","volume":"6","author":"Blansfield","year":"2005","journal-title":"J Immunother"},{"key":"10.1016\/j.ejim.2017.08.019_bb0180","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","article-title":"Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma","volume":"4","author":"Maker","year":"2006","journal-title":"J Immunother"},{"key":"10.1016\/j.ejim.2017.08.019_bb0185","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejim.2017.08.019_bb0190","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3174\/ajnr.A1623","article-title":"Ipilimumab-induced hypophysitis: MR imaging findings","volume":"9","author":"Carpenter","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0195","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"1","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.ejim.2017.08.019_bb0200","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4158\/EP11273.OR","article-title":"Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series","volume":"3","author":"Min","year":"2012","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ejim.2017.08.019_bb0205","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.endonu.2013.01.007","article-title":"Ipilimumab, a cause of autoimmune hypophysitis","volume":"10","author":"de Hollanda","year":"2013","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.ejim.2017.08.019_bb0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.clineuro.2014.06.011","article-title":"Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis","author":"Chodakiewitz","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.ejim.2017.08.019_bb0215","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s12020-014-0199-9","article-title":"Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports","volume":"3","author":"Marlier","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.ejim.2017.08.019_bb0220","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"2","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ejim.2017.08.019_bb0225","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0230","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejim.2017.08.019_bb0235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1758834011431718","article-title":"Ipilimumab: its potential in non-small cell lung cancer","volume":"2","author":"Tomasini","year":"2012","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0240","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"8","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.ejim.2017.08.019_bb0245","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"4","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejim.2017.08.019_bb0250","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.medcli.2015.02.010","article-title":"Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer","volume":"6","author":"Iglesias","year":"2015","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.ejim.2017.08.019_bb0255","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"28","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0260","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"5","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0265","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-017-1289-2","article-title":"Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab","author":"Brilli","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.ejim.2017.08.019_bb0270","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"5","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0275","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"25","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0280","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"4","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2017.08.019_bb0285","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1158\/1078-0432.CCR-09-1254","article-title":"Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma","volume":"19","author":"Ribas","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejim.2017.08.019_bb0290","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/bjc.2013.227","article-title":"Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours","volume":"10","author":"Millward","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejim.2017.08.019_bb0295","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1507\/endocrj.EJ16-0161","article-title":"Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma","volume":"10","author":"Okano","year":"2016","journal-title":"Endocr J"},{"key":"10.1016\/j.ejim.2017.08.019_bb0300","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/1346-8138.13437","article-title":"Case of hypophysitis caused by nivolumab","volume":"44","author":"Ishikawa","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0305","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"26","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.08.019_bb0310","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"4","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.08.019_bb0315","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1471-4906(01)01888-9","article-title":"PD-1: an inhibitory immunoreceptor involved in peripheral tolerance","volume":"5","author":"Nishimura","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0320","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma","volume":"1","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.08.019_bb0325","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0330","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1479-5876-11-108","article-title":"The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production","volume":"11","author":"Laurent","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejim.2017.08.019_bb0335","doi-asserted-by":"crossref","first-page":"76565","DOI":"10.18632\/oncotarget.12088","article-title":"Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors","volume":"7","author":"Mei","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejim.2017.08.019_bb0340","doi-asserted-by":"crossref","first-page":"174","DOI":"10.14694\/EdBook_AM.2012.32.79","article-title":"Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist","author":"Weber","year":"2012","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejim.2017.08.019_bb0345","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.6004\/jnccn.2014.0105","article-title":"Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash","volume":"8","author":"Nallapaneni","year":"2014","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ejim.2017.08.019_bb0350","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12032-010-9794-7","article-title":"Hyponatremia associated with Ipilimumab-induced hypophysitis","volume":"1","author":"Barnard","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0355","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/0028-3886.198182","article-title":"Ipilimumab-induced hypophysitis and ileocolitis: serial pituitary MRI findings","volume":"1","author":"Singh","year":"2017","journal-title":"Neurol India"},{"key":"10.1016\/j.ejim.2017.08.019_bb0360","doi-asserted-by":"crossref","first-page":"775","DOI":"10.20344\/amp.6541","article-title":"Ipilimumab-induced autoimmune hypophysitis: diagnostic and management challenges illustrated by a clinical case","volume":"6","author":"Marques","year":"2015","journal-title":"Acta Medica Port"},{"key":"10.1016\/j.ejim.2017.08.019_bb0365","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with Pembrolizumab","volume":"11","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2017.08.019_bb0370","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"4","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0375","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"35","author":"Ribas","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0380","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"5","author":"Orlov","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2017.08.019_bb0385","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"2","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0390","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","article-title":"Drug-induced graves disease from CTLA-4 receptor suppression","volume":"4","author":"Borodic","year":"2011","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ejim.2017.08.019_bb0395","first-page":"2087525","article-title":"Treatment of Ipilimumab induced Graves' disease in a patient with metastatic melanoma","volume":"2016","author":"Azmat","year":"2016","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0400","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-214603","article-title":"A rare case of thyroid storm","volume":"2016","author":"McMillen","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ejim.2017.08.019_bb0405","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-017-0213-x","article-title":"Nivolumab induced myxedema crisis","volume":"5","author":"Khan","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejim.2017.08.019_bb0410","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"3","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"0108","key":"10.1016\/j.ejim.2017.08.019_bb0420","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"16","author":"Trainer","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.ejim.2017.08.019_bb0425","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT","volume":"11","author":"Bacanovic","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ejim.2017.08.019_bb0430","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"4","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2017.08.019_bb0435","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejim.2017.08.019_bb0440","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/jdi.12531","article-title":"Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy","volume":"6","author":"Okamoto","year":"2016","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.ejim.2017.08.019_bb0445","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1620\/tjem.239.155","article-title":"Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes","volume":"2","author":"Miyoshi","year":"2016","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.ejim.2017.08.019_bb0450","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/1346-8138.13486","article-title":"Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient","volume":"44","author":"Teramoto","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejim.2017.08.019_bb0455","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00262-016-1913-7","article-title":"A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes","volume":"1","author":"Chae","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejim.2017.08.019_bb0460","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-016-0196-z","article-title":"Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy","volume":"4","author":"Lowe","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejim.2017.08.019_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am J Emerg Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517303217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517303217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T23:35:11Z","timestamp":1750808111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620517303217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":93,"alternative-id":["S0953620517303217"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2017.08.019","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2017.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}